FDA approval of Teva Pharmaceutical Industries Ltd.’s Synribo (omacetaxine mepesuccinate) is a validation of the chronic myeloid leukemia drug’s efficacy in a salvage setting, but its commercial prospects may be limited by a narrow population, modest efficacy and an increasingly crowded therapeutic space that is expected to grow even more so in the coming months.
The agency granted accelerated approval to Synribo, a protein synthesis inhibitor that is administered subcutaneously, on Oct. 26 for treatment...